68Ga-SATO antagonist in neuroblastoma
Key facts
- Where
- Utrecht, NetherlandsSee the site
- Phase
- Phase 1/2
Where in Netherlands
- Prinses Maxima Centrum voor Kinderoncologie B.V.Utrecht, NetherlandsNo longer taking part
Trial details
- Who runs it
- Prinses Maxima Centrum voor Kinderoncologie B.V.
- Trial code
- EU 2024-513843-10-00
- Record updated
- 17 June 2025
- Original description
Assess the short term safety and tolerability of 68Ga-SATO in pediatric patients with NBLRead full original descriptionShow less
68Ga-SATO in paediatric neuroblastoma patients; exploratory, safety, non-randomized, open label, comparative study - GAP NBL study
Assess the short term safety and tolerability of 68Ga-SATO in pediatric patients with NBL
Inclusion: Age 0-18 years; Written informed consent (by legal representative) and assent consent from the patient when applicable; Patients with a clinical suspicion of neuroblastoma who are referred for the first time for conventional M123IBGimaging and patients with known NBL who are referred for for follow-up M123IBG imaging.
Exclusion: Children with pre-existing severe auto-immune diseases; Use of therapeutic long-acting somatostatin analogs (e.g. Sandostatin®, Lanreotide®) within the 21 days beforethe planned infusion of 68Ga-SATO; Use of diuretics within 24 hours before the planned infusion of 68Ga-SATO; pregnancy of the patient.